Index Ventures led the Series A round with participation from Marathon, Pentech and EBRD to support team growth and market expansion.
"Finding a new drug can take over a decade in research, development and clinical trials, and requires thousands of experts working together with complex evidence,"
The Series A round was led by Acuity Investments to expand the company's DNA-based bio-monitoring products.
"Forensic scientists have used DNA to identify individuals at crime scenes for years – now we can use our technology to identify the whole range of species, from bacteria to birds, present in the environment using small samples of soil or water. Our technology can identify tiny fragments of DNA left behind by species and pinpoint exactly which species it is from."